121 related articles for article (PubMed ID: 38181444)
1. Amrubicin encapsulated PLGA NPs inhibits the PI3K/AKT signaling pathway by activating PTEN and inducing apoptosis in TMZ-resistant Glioma.
Younis M; Shaikh S; Shahzad KA; Tan F; Wang Z; Lashari MH
Biomed Mater; 2024 Jan; 19(2):. PubMed ID: 38181444
[TBL] [Abstract][Full Text] [Related]
2. Enhanced Caspase-Mediated Abrogation of Autophagy by Temozolomide-Loaded and Panitumumab-Conjugated Poly(lactic-
Banstola A; Duwa R; Emami F; Jeong JH; Yook S
Mol Pharm; 2020 Nov; 17(11):4386-4400. PubMed ID: 33079558
[TBL] [Abstract][Full Text] [Related]
3. Cordycepin Augments the Chemosensitivity of Human Glioma Cells to Temozolomide by Activating AMPK and Inhibiting the AKT Signaling Pathway.
Bi Y; Li H; Yi D; Sun Y; Bai Y; Zhong S; Song Y; Zhao G; Chen Y
Mol Pharm; 2018 Nov; 15(11):4912-4925. PubMed ID: 30336060
[TBL] [Abstract][Full Text] [Related]
4. FK228 augmented temozolomide sensitivity in human glioma cells by blocking PI3K/AKT/mTOR signal pathways.
Wu Y; Dong L; Bao S; Wang M; Yun Y; Zhu R
Biomed Pharmacother; 2016 Dec; 84():462-469. PubMed ID: 27685789
[TBL] [Abstract][Full Text] [Related]
5. Temozolomide induces activation of Wnt/β-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy.
Tomar VS; Patil V; Somasundaram K
Cell Biol Toxicol; 2020 Jun; 36(3):273-278. PubMed ID: 31758290
[TBL] [Abstract][Full Text] [Related]
6. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
7. MSC-AS1 knockdown inhibits cell growth and temozolomide resistance by regulating miR-373-3p/CPEB4 axis in glioma through PI3K/Akt pathway.
Li C; Feng S; Chen L
Mol Cell Biochem; 2021 Feb; 476(2):699-713. PubMed ID: 33106913
[TBL] [Abstract][Full Text] [Related]
8. Temozolomide treatment combined with AZD3463 shows synergistic effect in glioblastoma cells.
Goker Bagca B; Ozates NP; Asik A; Caglar HO; Gunduz C; Biray Avci C
Biochem Biophys Res Commun; 2020 Dec; 533(4):1497-1504. PubMed ID: 33109342
[TBL] [Abstract][Full Text] [Related]
9. Intranasal Delivery of Temozolomide-Conjugated Gold Nanoparticles Functionalized with Anti-EphA3 for Glioblastoma Targeting.
Wang L; Tang S; Yu Y; Lv Y; Wang A; Yan X; Li N; Sha C; Sun K; Li Y
Mol Pharm; 2021 Mar; 18(3):915-927. PubMed ID: 33417456
[TBL] [Abstract][Full Text] [Related]
10. IKBKE enhances TMZ-chemoresistance through upregulation of MGMT expression in glioblastoma.
Guo G; Sun Y; Hong R; Xiong J; Lu Y; Liu Y; Lu J; Zhang Z; Guo C; Nan Y; Huang Q
Clin Transl Oncol; 2020 Aug; 22(8):1252-1262. PubMed ID: 31865606
[TBL] [Abstract][Full Text] [Related]
11. Quercetin induces MGMT
Wang W; Yuan X; Mu J; Zou Y; Xu L; Chen J; Zhu X; Li B; Zeng Z; Wu X; Yin Z; Wang Q
Phytomedicine; 2023 Sep; 118():154933. PubMed ID: 37451151
[TBL] [Abstract][Full Text] [Related]
12. Development of transferrin-modified poly(lactic-co-glycolic acid) nanoparticles for glioma therapy.
Mao J; Meng X; Zhao C; Yang Y; Liu G
Anticancer Drugs; 2019 Jul; 30(6):604-610. PubMed ID: 30855310
[TBL] [Abstract][Full Text] [Related]
13. FOXM1-mediated NUF2 expression confers temozolomide resistance to human glioma cells by regulating autophagy via the PI3K/AKT/mTOR signaling pathway.
Guo L; Wu Z
Neuropathology; 2022 Oct; 42(5):430-446. PubMed ID: 35701983
[TBL] [Abstract][Full Text] [Related]
14. Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway.
Yu X; Wang M; Zuo J; Wahafu A; Mao P; Li R; Wu W; Xie W; Wang J
Life Sci; 2019 Nov; 236():116917. PubMed ID: 31614149
[TBL] [Abstract][Full Text] [Related]
15. Knockdown of circHIPK3 Facilitates Temozolomide Sensitivity in Glioma by Regulating Cellular Behaviors Through miR-524-5p/KIF2A-Mediated PI3K/AKT Pathway.
Yin H; Cui X
Cancer Biother Radiopharm; 2021 Sep; 36(7):556-567. PubMed ID: 32833501
[No Abstract] [Full Text] [Related]
16. MiR-223/PAX6 Axis Regulates Glioblastoma Stem Cell Proliferation and the Chemo Resistance to TMZ via Regulating PI3K/Akt Pathway.
Huang BS; Luo QZ; Han Y; Huang D; Tang QP; Wu LX
J Cell Biochem; 2017 Oct; 118(10):3452-3461. PubMed ID: 28332226
[TBL] [Abstract][Full Text] [Related]
17. lncRNA XLOC013218 promotes cell proliferation and TMZ resistance by targeting the PIK3R2-mediated PI3K/AKT pathway in glioma.
Zhou J; Xu N; Liu B; Wang C; He Z; Lenahan C; Tang W; Zeng H; Guo H
Cancer Sci; 2022 Aug; 113(8):2681-2692. PubMed ID: 35637600
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of phosphatidylinositol 3-kinase by PX-866 suppresses temozolomide-induced autophagy and promotes apoptosis in glioblastoma cells.
Harder BG; Peng S; Sereduk CP; Sodoma AM; Kitange GJ; Loftus JC; Sarkaria JN; Tran NL
Mol Med; 2019 Nov; 25(1):49. PubMed ID: 31726966
[TBL] [Abstract][Full Text] [Related]
19. Salvianolic acid A (Sal A) suppresses malignant progression of glioma and enhances temozolomide (TMZ) sensitivity via repressing transgelin-2 (TAGLN2) mediated phosphatidylinositol-3-kinase (PI3K) / protein kinase B (Akt) pathway.
Ye T; Chen R; Zhou Y; Zhang J; Zhang Z; Wei H; Xu Y; Wang Y; Zhang Y
Bioengineered; 2022 May; 13(5):11646-11655. PubMed ID: 35505656
[TBL] [Abstract][Full Text] [Related]
20. Targeting MAGI2-AS3-modulated Akt-dependent ATP-binding cassette transporters as a possible strategy to reverse temozolomide resistance in temozolomide-resistant glioblastoma cells.
Chen Z; Zhou J; Liu Y; Ni H; Zhou B
Drug Dev Res; 2023 Nov; 84(7):1482-1495. PubMed ID: 37551766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]